PE20030608A1 - Composicion y metodo para tratar diabetes - Google Patents
Composicion y metodo para tratar diabetesInfo
- Publication number
- PE20030608A1 PE20030608A1 PE2002001014A PE2002001014A PE20030608A1 PE 20030608 A1 PE20030608 A1 PE 20030608A1 PE 2002001014 A PE2002001014 A PE 2002001014A PE 2002001014 A PE2002001014 A PE 2002001014A PE 20030608 A1 PE20030608 A1 PE 20030608A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- composition
- islets
- polypeptide
- treat diabetes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 230000009707 neogenesis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO QUE TIENE POR LO MENOS QUINCE AMINOACIDOS CONSECUTIVOS DE UNA PROTEINA ASOCIADA A LA NEOGENESIS DE ISLOTES MAMIFEROS QUE OCURRE NATURALEMENTE DONDE LA SECUENCIA DE AMINOACIDOS ES SEQ ID NO:1; SEQ ID NO:2, SEQ IDE NO:3 Y FRAGMENTOS DE ESTE, CON UN pH DE 4-6. LA COMPOSICION COMPRENDE DE 0,1 mg A 300 mg DEL POLIPEPTIDO Y ESTA EN FORMA DE POLVO LIOFILIZADO. LA FORMULACION REGENERA LOS ISLOTES DE LANGERHANS, CELULAS BETA PANCREATICAS O ESTABLECE REGULACION DE LA GLUCOSA Y ES UTIL EN EL TRATAMIENTO DE DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32933001P | 2001-10-16 | 2001-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030608A1 true PE20030608A1 (es) | 2003-08-26 |
Family
ID=23284879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002001014A PE20030608A1 (es) | 2001-10-16 | 2002-10-15 | Composicion y metodo para tratar diabetes |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040132644A1 (es) |
| EP (1) | EP1435995A2 (es) |
| JP (1) | JP2005506362A (es) |
| KR (1) | KR20050036865A (es) |
| CN (1) | CN1723034A (es) |
| BR (1) | BR0213291A (es) |
| CA (1) | CA2463769A1 (es) |
| CO (2) | CO5570658A2 (es) |
| CZ (1) | CZ2004479A3 (es) |
| HU (1) | HUP0401612A3 (es) |
| IL (1) | IL161073A0 (es) |
| MA (1) | MA27503A1 (es) |
| MX (1) | MXPA04003526A (es) |
| NO (1) | NO20042012L (es) |
| PE (1) | PE20030608A1 (es) |
| PL (1) | PL370069A1 (es) |
| RU (1) | RU2004114865A (es) |
| SK (1) | SK1702004A3 (es) |
| WO (1) | WO2003033808A2 (es) |
| ZA (1) | ZA200402261B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037277A2 (en) * | 2002-10-24 | 2004-05-06 | Mcgill University | Use of ingap for reversing diabetes |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| EP1883417A2 (en) * | 2005-05-25 | 2008-02-06 | Curedm Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
| EP1840573A1 (en) * | 2006-03-27 | 2007-10-03 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| WO2008064306A2 (en) * | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
| EA201000399A1 (ru) * | 2007-08-30 | 2011-02-28 | Кьюрдм, Инк. | Композиции и способы использования проостровковых пептидов и их аналогов |
| CA2886442A1 (en) * | 2012-09-27 | 2014-04-03 | Claresa LEVETAN | Generation of new pancreatic beta cells |
| CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN104045699A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| CN104045698B (zh) * | 2013-03-15 | 2019-04-16 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN103305457B (zh) * | 2013-06-06 | 2015-07-08 | 浙江省医学科学院 | 一种体外扩增胰岛β细胞的方法 |
| US9321812B2 (en) * | 2014-03-28 | 2016-04-26 | Perle Bioscience | Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide |
| WO2017152861A1 (en) * | 2016-03-10 | 2017-09-14 | Shenzhen Hightide Biopharmaceutical, Ltd. | Conjugates of islet neogenesis peptides and analogs, and methods thereof |
| WO2020036918A1 (en) * | 2018-08-15 | 2020-02-20 | Wake Forest University Health Sciences | Improved formulations for pancreatic islet encapsulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US127624A (en) * | 1872-06-04 | Improvement in apparatus for elevating water | ||
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| US6106840A (en) * | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| JP4111539B2 (ja) * | 1995-02-22 | 2008-07-02 | イースタン・ヴァージニア・メディカル・スクール・オブ・ザ・メディカル・カレッジ・オブ・ハンプトン・ローズ | 膵島新生に関与するｉｎｇａｐタンパク質 |
| EP1612272B1 (en) * | 1996-05-03 | 2011-06-22 | Abbott Laboratories | Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| US6090577A (en) * | 1997-05-22 | 2000-07-18 | Incyte Pharmaceuticals, Inc. | Disease associated acidic protein |
| US6986994B2 (en) * | 2001-01-09 | 2006-01-17 | Gmp Endotherapeutics, Inc. | INGAP displacement assays |
-
2002
- 2002-09-24 US US10/253,733 patent/US20040132644A1/en not_active Abandoned
- 2002-10-15 PE PE2002001014A patent/PE20030608A1/es not_active Application Discontinuation
- 2002-10-15 MX MXPA04003526A patent/MXPA04003526A/es unknown
- 2002-10-15 JP JP2003536523A patent/JP2005506362A/ja active Pending
- 2002-10-15 EP EP02780465A patent/EP1435995A2/en not_active Ceased
- 2002-10-15 CA CA002463769A patent/CA2463769A1/en not_active Abandoned
- 2002-10-15 PL PL02370069A patent/PL370069A1/xx not_active Application Discontinuation
- 2002-10-15 CZ CZ2004479A patent/CZ2004479A3/cs unknown
- 2002-10-15 HU HU0401612A patent/HUP0401612A3/hu unknown
- 2002-10-15 WO PCT/US2002/032904 patent/WO2003033808A2/en not_active Ceased
- 2002-10-15 BR BR0213291-5A patent/BR0213291A/pt not_active IP Right Cessation
- 2002-10-15 CN CNA028201922A patent/CN1723034A/zh active Pending
- 2002-10-15 RU RU2004114865/15A patent/RU2004114865A/ru not_active Application Discontinuation
- 2002-10-15 IL IL16107302A patent/IL161073A0/xx unknown
- 2002-10-15 KR KR1020047005586A patent/KR20050036865A/ko not_active Ceased
- 2002-10-15 SK SK170-2004A patent/SK1702004A3/sk not_active Application Discontinuation
-
2004
- 2004-03-23 ZA ZA200402261A patent/ZA200402261B/en unknown
- 2004-04-02 CO CO04031543A patent/CO5570658A2/es not_active Application Discontinuation
- 2004-04-09 MA MA27627A patent/MA27503A1/fr unknown
- 2004-05-14 NO NO20042012A patent/NO20042012L/no not_active Application Discontinuation
- 2004-06-25 CO CO04060289A patent/CO5590933A2/es not_active Application Discontinuation
-
2007
- 2007-12-04 US US11/999,208 patent/US20080171704A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2004479A3 (cs) | 2005-01-12 |
| HUP0401612A2 (hu) | 2004-12-28 |
| PL370069A1 (en) | 2005-05-16 |
| WO2003033808A2 (en) | 2003-04-24 |
| CO5570658A2 (es) | 2005-10-31 |
| WO2003033808A3 (en) | 2003-09-18 |
| CN1723034A (zh) | 2006-01-18 |
| CA2463769A1 (en) | 2003-04-24 |
| HUP0401612A3 (en) | 2006-04-28 |
| IL161073A0 (en) | 2004-08-31 |
| JP2005506362A (ja) | 2005-03-03 |
| BR0213291A (pt) | 2004-10-26 |
| KR20050036865A (ko) | 2005-04-20 |
| US20080171704A1 (en) | 2008-07-17 |
| SK1702004A3 (sk) | 2005-03-04 |
| EP1435995A2 (en) | 2004-07-14 |
| MXPA04003526A (es) | 2004-07-22 |
| MA27503A1 (fr) | 2005-09-01 |
| ZA200402261B (en) | 2004-09-28 |
| NO20042012L (no) | 2004-07-16 |
| RU2004114865A (ru) | 2005-05-27 |
| CO5590933A2 (es) | 2005-12-30 |
| US20040132644A1 (en) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030608A1 (es) | Composicion y metodo para tratar diabetes | |
| NO980155L (no) | Stabilisert farmasöytisk preparat som omfatter et veksthormon som er forbehandlet med sink og eventuelt lysin eller kasiumioner | |
| DE69922043D1 (de) | Glp-1 analoge | |
| DK1654287T3 (da) | CD20-bindende polypeptidsammensætninger | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| PT699686E (pt) | Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos | |
| TR199802789T2 (xx) | Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar. | |
| BRPI0510817A (pt) | protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| DE69938064D1 (de) | Aminoterminal modifizierte parathyroidhormon (pth) analoge | |
| PE20120425A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga | |
| PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| BR9809951A (pt) | Método para tratamento da obesidade | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| ATE322503T1 (de) | Gefrierschutzprotein | |
| BR9105783A (pt) | Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica | |
| ATE210149T1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
| BR0305039A (pt) | Uso de compostos que possuem a atividade biológica de peptìdeo vasoativo intestinal para o tratamento da sarcoidose | |
| PT817646E (pt) | Metodos de tratamento da inflamacao e formulacoes para esse fim | |
| ATE494301T1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
| ES2421407T3 (es) | Agente y composición para la curación de heridas | |
| NZ518772A (en) | Polypeptide fragments comprising c-terminal portion of helicobacter catalase | |
| WO1998053838A3 (en) | A soluble laminin receptor precursor and methods to inhibit its interactions | |
| ATE420890T1 (de) | Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide | |
| MXPA02000801A (es) | Homologo humano de polinucleotidos, nesp55 de proteina secretora de neuroendocrino bovino y usos el mismo relacionado con la obesidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |